{"id":585975,"date":"2025-07-02T15:16:53","date_gmt":"2025-07-02T21:16:53","guid":{"rendered":"https:\/\/cerebrodigital.net\/?p=585975"},"modified":"2025-07-03T12:59:53","modified_gmt":"2025-07-03T18:59:53","slug":"terminal-cancer-dog-dewormer-cure","status":"publish","type":"post","link":"https:\/\/cerebrodigital.net\/en\/terminal-cancer-dog-dewormer-cure\/","title":{"rendered":"Terminal Cancer: Can a Dog Dewormer Cure It? The Case of Joe Tippens"},"content":{"rendered":"\n

Joe Tippens was diagnosed in 2016 with terminal, metastatic small-cell lung cancer<\/strong>. After losing all hope from mainstream medicine, he began taking fenbendazole\u2014a common veterinary dewormer\u2014along with curcumin and CBD oil. Five months later, his scans showed no trace of disease. This is the \u201cmiracle\u201d story inspiring thousands of patients and challenging traditional oncology.
<\/p>\n\n\n\n

\"Terminal<\/figure>\n\n\n\n

From Career Peak to Devastating Diagnosis<\/strong><\/h2>\n\n\n\n

Tippens was about to relocate to Switzerland for an executive promotion when an incidental CT scan revealed a fist-sized tumor in his left lung. Shortly after, small-cell lung cancer was confirmed\u2014a highly aggressive form. Though initial chemotherapy and radiation reduced the primary tumor, by December 2016 scans showed extensive metastases in his neck, liver, pancreas, and bones.<\/p>\n\n\n\n

His prognosis: less than four months to live and a 0% survival rate. Doctors recommended palliative care and getting his affairs in order. But Tippens refused to surrender.<\/p>\n\n\n\n

Just one day later, he received a life-changing call: a veterinarian mentioned that fenbendazole\u2014used for deworming animals\u2014had shown tumor elimination in mice in accidental studies. With nothing to lose, he started the drug in January 2017.<\/p>\n\n\n\n

Fenbendazole and the \u201cImpossible Remission\u201d<\/strong><\/h2>\n\n\n\n

Following an initial protocol, Tippens combined fenbendazole with bioavailable curcumin and CBD oil<\/a>. He began with a low dose three times per week (to avoid liver toxicity), later switching to a daily regimen. In May 2017, a CT scan at MD Anderson Cancer Center showed no evidence of disease<\/strong>.<\/p>\n\n\n\n

In just four months, his metastatic cancer vanished\u2014leaving doctors stunned. He was the only one among 1,100 trial participants to experience a complete remission. Still, Tippens didn\u2019t disclose the protocol immediately. He underwent monthly scans until the absence of cancer was confirmed.<\/p>\n\n\n\n

Eventually, he revealed his treatment to his oncologists. Interestingly, the same center had already explored fenbendazole years earlier, and Indian researchers (previously at MD Anderson) identified three anticancer mechanisms<\/strong>: disrupting microtubules needed for cancer cell division, interfering with cancer cell sugar metabolism, and activating the p53 tumor suppressor gene, which is often inactive or mutated in cancer patients.<\/p>\n\n\n\n

\"-\"
Fenbendazole metabolites. Structures based on the metabolic pathway shown in the FAO UN document on Fenbendazole.<\/figcaption><\/figure>\n\n\n\n

Viral Spread, Witnesses, and the Power of Testimony<\/strong><\/h2>\n\n\n\n

By 2018, Tippens began receiving hundreds of calls from cancer patients. He created the blog \u201cMy Cancer Story Rocks\u201d and later a Facebook group\u2014but demand only skyrocketed. His story went viral in 96 countries. The Facebook community now exceeds 40,000 members and has documented over 5,000 cases of surprising remissions.<\/p>\n\n\n\n

Internationally, in China alone, more than 50,000 people follow the so-called \u201cUncle Joey Protocol.\u201d Tippens secured private funding for Oklahoma Medical Foundation researchers to analyze cases, and analysts from Stanford University later published preliminary studies on fenbendazole\u2019s anticancer potential. Tippens emphasizes his protocol is not a replacement<\/strong> for conventional medicine, but an affordable and low-risk complement to existing treatments.<\/p>\n\n\n\n

Why Isn\u2019t a $7-a-Week Drug Approved?<\/strong><\/h3>\n\n\n\n

The primary barrier isn\u2019t clinical\u2014it\u2019s economic. Fenbendazole has been on the market for over 25 years, with no patent protection, and was never approved for human use by the FDA. Clinical trials would cost between $300 and $400 million<\/strong>, and no pharmaceutical company wants to fund it without profit potential. Aware of this, Tippens is advocating for U.S. federal funding<\/strong> to test the drug. He points out Medicare spends billions on expensive cancer treatments that could be significantly reduced if a cheap veterinary dewormer proved effective.<\/p>\n\n\n\n

A Story of Questions\u2014and Hope<\/strong><\/h2>\n\n\n\n
\"-\"
Joe Tippens<\/figcaption><\/figure>\n\n\n\n

Joe Tippens remains in complete remission, lives a normal life, and continues the protocol as a preventive measure. His story ignites controversy\u2014and hope. It highlights the tension between empirical testimonies and clinical science, between pharmaceutical economics and treatment accessibility. Can a veterinary dewormer be part of the answer to cancer? For now, the formal evidence is limited\u2014but growing.<\/p>\n\n\n\n

Meanwhile, Tippens insists one factor was as crucial as any molecule: an unshakeable belief<\/strong> that he could heal. The mind as an ally, not a bystander. And that, regardless of the protocol, matters too.<\/p>\n\n\n\n

Reference:<\/p>\n\n\n\n